Please login to the form below

Not currently logged in
Email:
Password:

Complaints about UK medical advertising drop

And this year the MHRA will be vetting adverts to promote a ‘right first time’ approach

mhra logoThe Medicines and Healthcare products Regulatory Agency (MHRA)'s annual medical advertising report shows a decrease in complaints received last year.

Although complaints dropped to 193, down from 283 from the previous year, the report entitled 'Delivering high standards in medicines advertising' detailed serious breaches in regulations by healthcare bodies.

Johnson & Johnson filed a complaint to the MHRA concerning a TV advertisement produced by Omega Pharma for Bronchostop, a traditional herbal medicine licensed on the basis of evidence of traditional usage that wrongly suggesting the efficacy of the treatment had been demonstrated.

Another complaint lodged to the MHRA cited a meeting for healthcare professionals, where medicines were promoted and attendees were expected to make a 'minimum' purchase, which is not in line with the law.

Beryl Keeley, head of the MHRA's advertising standards unit, commented: “People have the right to know that the advertisements they see are accurate and do not contain any information that could be misleading and that is why we and the self-regulatory bodies take the action that we do.

“In the coming year, we expect to vet advertising for around 50 products to promote a 'right first time' approach and protect against misleading messages in advertising.”

Complaints to the MHRA are resolved through voluntary agreements, by companies either correcting or removing their adverts without the need for further regulatory action.

Article by
Kirstie Pickering

3rd March 2015

From: Marketing, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics